This week, Martin takes a step back and look at the early GLP-1 era—where the drama is coming from, how costs are reshaping coverage, and why the care model around these drugs matters as much as the molecule itself.
Evan Richardson, Founder and CEO of Form Health, shares how his time at Castlight and Grand Rounds/Included Health shaped a thesis that higher-quality care drives better outcomes and lower long-term costs, and why he built Form Health to scale obesity medicine before Ozempic went mainstream.
They dig into the real-world gap in GLP-1 outcomes and persistence without wraparound care, Form’s high-touch telemedicine approach, and how employers and payers are grappling with explosive demand, falling cash-pay prices via LillyDirect/NovoCare, and center-of-excellence models to control spend and prove ROI.
For more from Health Tech Nerds, subscribe to our weekly newsletters: https://www.healthtechnerds.com/subscribe